ETFChannel.com
AMGN Description — Amgen Inc

Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).

Company Name: 
Amgen Inc
Website: 
www.amgen.com
Sector: 
Biotechnology
Number of ETFs Holding AMGN: 
145
Total Market Value Held by ETFs: 
$18,474,350,898.02
Total Market Capitalization: 
$123,558,000,000
% of Market Cap. Held by ETFs: 
14.95%
 ETF   AMGN Weight   AMGN Amount 
 VTI   0.33%   $3,607,983,515         
 VOO   0.39%   $2,734,782,620         
 QQQ   1.20%   $1,768,270,270         
 SPY   0.40%   $1,315,923,428         
 DIA   5.11%   $1,301,548,567         
 IVV   0.40%   $1,082,052,108         
 VTV   0.79%   $1,064,409,250         
 XLV   2.61%   $968,134,734         
 VYM   0.94%   $516,561,280         
 VHT   2.25%   $413,044,564         
List of all 145 ETFs holding AMGN »
Quotes delayed 20 minutes

Email EnvelopeFree AMGN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Hold (2.33 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts Forecast:
AMGN Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding AMGN | Amgen Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.